The largest database of trusted experimental protocols

Hiv type 1 p24 antigen elisa

Manufactured by ZeptoMetrix
Sourced in United States

The HIV Type 1 p24 Antigen ELISA is a laboratory tool used for the detection and quantification of the p24 antigen, a structural protein found in the HIV-1 virus. It utilizes the enzyme-linked immunosorbent assay (ELISA) technique to measure the presence and concentration of the p24 antigen in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using hiv type 1 p24 antigen elisa

1

Production and Infection of VSV-G Pseudotyped HIV-1 Luciferase Reporter Viruses

Check if the same lab product or an alternative is used in the 5 most similar protocols
The VSV-G pseudotyped HIV-1-ΔVif luciferase reporter viruses with A3G or its mutants were produced by co-transfection of pNL4-3/ΔenvΔvif-Luc and pVSV-G with the A3G expression vector (pcDNA3/HA-A3G) in HEK293T cells as previously described (Shindo et al., 2003 (link); Kobayashi et al., 2004 (link)). The target M8166 cells were infected with reporter viruses normalized by p24 amount, which was measured by HIV Type 1 p24 Antigen ELISA (ZeptoMetrix). The infectivity was measured by luciferase activity and values were normalized to the infectivity of the virus produced in the absence of A3G expression.
+ Open protocol
+ Expand
2

APOBEC3G Inhibits HIV-1 Replication

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasmids pcDNA3.1-APOBEC3G-HA and pNL4-3 were transfected into 293T cells and cultured with or without hop-8. The cells were collected and the expression of A3G-HA, p55, p24, Vif, and beta-actin was analyzed by western blot. The supernatant was collected and centrifuged at 2000 g and the cell debris discarded. To normalize viral input, the levels of p24 were determined using HIV Type 1 p24 Antigen ELISA (ZeptoMetrix Corporation, Buffalo, NY, USA). TZM-bl cells were infected with supernatant containing 20 ng of HIV-1 p24, and the residual infection was determined using relative luciferase activity. To determine the incorporation of A3G in progeny virion, plasmids pcDNA3.1-APOBEC3G-HA and pNL4-3 were transfected into 293T cells and cultured with or without hop-8 for 48 h. The supernatant was collected and centrifuged at 2000× g. The cell debris was discarded. The viral particles were lysed with 0.5% Triton-X100. A3G and p24 levels in the supernatant were determined by western blot.
+ Open protocol
+ Expand
3

Production and Infectivity Assay of Pseudotyped HIV-1 Viruses

Check if the same lab product or an alternative is used in the 5 most similar protocols
The pseudotyped HIV-1 Gag-iFRET labeled virus was produced by co-transfecting HEK293T cells with pHIV-1 Gag-iFRETΔEnv and pNL4-3ΔEnv parental plasmids at three different ratios as described in section “Cell Cultures and Virus Production,” together with the HIV-1 envelope expression plasmid, pSVIII-92HT593.1. The pSVIII-92HT593.1 construct was obtained from Dr. Beatrice Hahn through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 92HT593.1 gp160 Expression Vector (cat# 3077) (Gao et al., 1996 (link)). HIV-1 Gag-iFRETΔPro labeled virus was produced by co-transfecting HEK293T cells with pHIV-1 Gag-iFRETΔPro and pNL4-3ΔPro parental plasmid at the same ratios as HIV-1 Gag-iFRET. The viral titer was measured by HIV Type 1 p24 Antigen ELISA (ZeptoMetrix). The following day after 5 × 103 TZM-bl cells seeded in 96 well plates, an equal amount of virus (total of 5 ng HIV-1 p24) was added to the TZM-bl target cells, and then cultured at 37°C for 48 h in a CO2 incubator. Luciferase activity in the infected cells was measured with the Luciferase Assay System (Promega) on a 2030 ARVO X3 plate reader (Perkin Elmer) to quantify virus infectivity.
+ Open protocol
+ Expand
4

Macrophage Infection and CSC Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary monocytes were differentiated into macrophages and infected with HIV-1, prior to treatment with CSC (Murty Pharmaceuticals, KY), using previously reported protocol [33 (link), 34 (link)]. Briefly, PBMCs were plated in T-75 flask and non-adherent cells were removed after 1 h at 37°C. Cells were cultured for 6–8 days in media containing human mCSF to facilitate macrophage differentiation. Mature macrophages were collected and activated by treating with polybrene (2 μg/ml) for 30 min before HIV infection. Macrophages were infected with TCID50 of HIV-1 for 2 h and cultured in 6-well plates (1 million/well) for 6 days. Cell supernatant was collected on days 0, 3, and 6 to analyze p24 levels. Starting day 7, HIV-infected macrophages were treated, once daily, with 25 ug/ml CSC or equivalent amount of DMSO. During the treatment period, one-half milliliters of fresh media was added daily to each well to avoid cytotoxicity. Supernatant collected on day 11 (24 h after last treatment) was analyzed for viral load using the HIV type 1 p24 antigen ELISA (ZeptoMetrix, NY).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!